308080.KQ ViGenCell Inc.
- Market cap
- KRW 95.4B
- P/E
- -
- P/B
- 2.46x
- ROE
- -25.4%
- Dividend yield
- -
- Fundamental score
- 0.9/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 308080.KQ undervalued?
Graham numberThe Graham number of ViGenCell Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ViGenCell Inc. fundamental analysis
4 of 21 checks passedROE 0/2
Low return on equity (-25.4%), below 10%.
ROA 0/1
Return on assets (-19.9%) is below the industry median (1.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-9.1%) is below the industry median (1.8%).
Revenue Growth 0/2
Revenue did not grow over the past 3 years or is not reported.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (19.1%), 40% or less.
Debt Trend 0/1
Debt to equity history is shorter than 5 years.
Cash Runway 1/2
Cash covers 2.0 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (2.5x) is above the industry median (0.9x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
ViGenCell Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ViGenCell Inc.
ViGenCell Inc. provides immune cell therapy in South Korea. It develops ViTier, an antigen-specific killer T cell therapy, such as VT-EBV-N for NK/T Lymphoma indications and VT-Tri(1)-A for AML indications; ViMedier, a cord blood-derived myeloid suppressor cell therapy, including VM-GD for GvHD indications and VM-AD for atopic dermatitis indications; and ViRanger, an off-the-shelf allogenic universal T cell gene therapy comprising VR-CAR and VR-GDT for hepatoma and leukemia …
Full company profileViGenCell Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ViGenCell Inc. annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 15.0M | 0.00 | 0.00 | - | 0.00 | 279M | 22.7M | 1.80B |
| Gross Profit | 15.0M | 0.00 | 0.00 | - | 0.00 | 11.9M | 11.1M | 67.9M |
| Operating Income | -15.0B | -7.91B | -13.1B | -18.2B | -20.1B | -15.3B | -17.1B | -10.7B |
| EBITDA | - | - | - | -14.2B | -13.4B | -10.1B | -13.0B | -6.94B |
| Net Income | -22.4B | -10.5B | -11.1B | -17.4B | -17.9B | -14.1B | -16.3B | -9.86B |
| EPS | -1,189 | -554 | -589 | -915 | -933 | -730 | -796 | -481 |
| Balance Sheet | ||||||||
| Total Assets | 26.5B | 23.1B | 117B | 99.4B | 81.0B | 67.3B | 54.3B | 49.7B |
| Total Liabilities | 51.8B | 57.1B | 12.1B | 9.73B | 9.56B | 9.32B | 10.6B | 10.9B |
| Shareholders' Equity | -25.3B | -34.1B | 105B | 89.6B | 71.5B | 58.0B | 43.7B | 38.8B |
| Cash & Short-term Investments | 24.6B | 16.2B | 65.4B | 69.1B | 53.4B | 45.2B | 3.93B | 15.6B |
| Total Debt | - | 328M | - | - | - | - | - | - |
| Cash Flow | ||||||||
| Operating Cash Flow | -2.96B | -8.19B | -7.95B | -11.1B | -15.3B | -10.9B | -13.8B | -7.82B |
| Capital Expenditure | 988M | 1.77B | 11.5B | 13.7B | 1.02B | 113M | 822M | 50.6M |
| Free Cash Flow | - | -9.97B | -23.4B | -24.8B | -16.3B | -11.0B | -14.6B | -7.87B |
| Ratios | ||||||||
| ROE | - | - | -10.6% | -19.4% | -25.0% | -24.2% | -37.3% | -25.4% |
| ROA | -84.7% | -45.4% | -9.5% | -17.5% | -22.1% | -20.9% | -30.1% | -19.9% |
| Net Profit Margin | -149,218.8% | - | - | - | - | -5,038.8% | -71,986.4% | -547.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ViGenCell Inc. dividends
ViGenCell Inc. has not paid dividends in the last 7 fiscal years.
Last stock split: 2:1 on Jun 8, 2022.
Who owns ViGenCell Inc.
- Insiders 26.13%
- Institutions 0.02%
- Public & others 73.85%
- Shares outstanding 20.5M
- Free float 16.3M
ViGenCell Inc. company profile
- Company name
- ViGenCell Inc.
- Ticker
- 308080.KQ
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Oil, Gas & Consumable Fuels
- Employees
- 64
- Fiscal year end
- December
- Address
- The Reason Valley Knowledge Industry Complex, Seoul, South Korea, 08513
- Phone
- 82 2 785 0201
- Website
- vigencell.com
About ViGenCell Inc.
ViGenCell Inc. provides immune cell therapy in South Korea. It develops ViTier, an antigen-specific killer T cell therapy, such as VT-EBV-N for NK/T Lymphoma indications and VT-Tri(1)-A for AML indications; ViMedier, a cord blood-derived myeloid suppressor cell therapy, including VM-GD for GvHD indications and VM-AD for atopic dermatitis indications; and ViRanger, an off-the-shelf allogenic universal T cell gene therapy comprising VR-CAR and VR-GDT for hepatoma and leukemia indications. The company was founded in 2013 and is based in Seoul, South Korea.
ViGenCell Inc. management
6- Mr. Kim Tai Gyu M.D., Ph.D.Chief Executive Officer
- Ms. Sohn Hyun Jung Ph.D.Head of ViTier Platform Group, Translational & Clinical Group
- Mr. Cho Hyun II, Ph.D.Head of ViRanger Platform Group
- Mr. Kyung-Mook KimVP and Head of Business Support Group & Management Administration · born 1969
- Hee-Baeg Choi Ph.D.Head of Precision Medicine Diagnostics Group & GMP Center
- Su-Eon Kim Ph.D.Head of ViMedier Platform Group